SKINHEALTH SYSTEMS INC (SKIN)

NASDAQHealth CareMedical - SpecialtiesSnapshot 2026-10-15

$10.56-16.19%

Close 2026-10-16 · 1-day change

Read the published Living FV report summary

Investment OutlookAs of Oct 15, 2026

What could strengthen or challenge SKINHEALTH SYSTEMS INC’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Oct 4, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Living FV™

Living Fair Value by QuarterlyIQ

A valuation that evolves as the business changes.

A published Living FV snapshot is not available yet. The valuation workflow remains discoverable; a market target cannot supply the missing evidence.

View Living FV report and workflow

What the Thesis Depends On

Three key conditions need to be met for the investment thesis to play out.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Retention of key management personnel	A supporting condition in SKINHEALTH SYSTEMS INC's published investment case. The stated target is no further key executive departures.	Under Pressure	another key executive departs	1 key executive departure vs 0 target COO Sheri Lewis resigned to pursue other opportunities on 2026-08-14, constituting a loss of senior management. Context reviewed through Oct 15, 2026Last status assessment Oct 15, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Operating income improvement to $3.57M	Operating income is improving, with a target of $3.57M in Q2 2026.	Improving	operating income falls below $1M next quarter	Operating income: $3.572M FY2026-Q2; GAAP. Published target: >=3.57M. Target period is not explicitly aligned with this observation. Source published Aug 6, 20263,572,000 USD · source valueSource reportLast status assessment Oct 15, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 0a57ef4d-b1fd-4a54-9937-4d08fefd97aa. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated in 8 of last 8 quarters. Operating income improved significantly from negative $21.52M in 2024-Q3 to positive $3.57M in 2026-Q2, while net losses narrowed from $18.29M to $2.67M over the same period. The trajectory shows delivering progress on improving profitability and reducing losses. Delivery assessment Oct 15, 2026
Revenue stabilization around $290M	A primary condition in SKINHEALTH SYSTEMS INC's published investment case. The stated target is >=290M.	Under Pressure	falls below $280M for the fiscal year	Revenue: $72.113M FY2026-Q2; GAAP. Published target: >=290M. Target period is not explicitly aligned with this observation. Source published Aug 6, 202672,113,000 USD · source valueSource reportLast status assessment Oct 15, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 0a57ef4d-b1fd-4a54-9937-4d08fefd97aa. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated in 8 of last 8 quarters. Revenue has fluctuated between $64.9M in 2026-Q1 and $83.5M in 2024-Q4 with no clear upward trend. Management's focus on revenue growth and stabilization shows limited progress given the volatility and lack of consistent growth. Delivery assessment Oct 15, 2026

Stored thesis · Oct 4, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS: comparable history unavailable.

FY2027 revenue$0.30B

$0.30B → $0.30B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-08-27	Unavailable	$298,920,811	4 / 7
2026-08-28	Unavailable	$298,920,811	4 / 7
2026-08-29	Unavailable	$298,920,811	4 / 7
2026-08-30	Unavailable	$298,920,811	4 / 7
2026-08-31	Unavailable	$298,920,811	4 / 7
2026-09-01	Unavailable	$298,920,811	4 / 7
2026-09-02	Unavailable	$298,920,811	4 / 7
2026-09-03	Unavailable	$298,920,811	4 / 7
2026-09-04	Unavailable	$298,920,811	4 / 7
2026-09-05	Unavailable	$298,920,811	4 / 7
2026-09-06	Unavailable	$298,920,811	4 / 7
2026-09-07	Unavailable	$298,920,811	4 / 7
2026-09-08	Unavailable	$298,920,811	4 / 7
2026-09-09	Unavailable	$298,920,811	4 / 7
2026-09-10	Unavailable	$298,920,811	3 / 7
2026-09-11	Unavailable	$298,920,811	3 / 7
2026-09-12	Unavailable	$298,920,811	3 / 7
2026-09-13	Unavailable	$298,920,811	3 / 7
2026-09-14	Unavailable	$298,920,811	3 / 7
2026-09-15	Unavailable	$298,920,811	3 / 7
2026-09-16	Unavailable	$298,920,811	4 / 7
2026-09-17	Unavailable	$298,920,811	4 / 7
2026-09-18	Unavailable	$298,920,811	4 / 7
2026-09-19	Unavailable	$298,920,811	4 / 7
2026-09-20	Unavailable	$298,920,811	4 / 7
2026-09-21	Unavailable	$298,920,811	4 / 7
2026-09-22	Unavailable	$298,920,811	4 / 7
2026-09-23	Unavailable	$298,920,811	4 / 7
2026-09-24	Unavailable	$298,920,811	4 / 7
2026-09-25	Unavailable	$298,920,811	4 / 7
2026-09-26	Unavailable	$298,920,811	4 / 7
2026-09-27	Unavailable	$298,920,811	4 / 7
2026-09-28	Unavailable	$298,920,811	4 / 7
2026-09-29	Unavailable	$298,920,811	4 / 7
2026-09-30	Unavailable	$298,920,811	4 / 7
2026-10-01	Unavailable	$298,920,811	4 / 7
2026-10-02	Unavailable	$298,920,811	4 / 7
2026-10-03	Unavailable	$298,920,811	4 / 7
2026-10-04	Unavailable	$298,920,811	4 / 7
2026-10-05	Unavailable	$298,920,811	4 / 7
2026-10-06	Unavailable	$298,920,811	4 / 7
2026-10-07	Unavailable	$298,920,811	4 / 7
2026-10-08	Unavailable	$298,920,811	4 / 7
2026-10-09	Unavailable	$298,920,811	4 / 7
2026-10-10	Unavailable	$298,920,811	4 / 7
2026-10-11	Unavailable	$298,920,811	4 / 7
2026-10-12	Unavailable	$298,920,811	4 / 7
2026-10-13	Unavailable	$298,920,811	4 / 7
2026-10-14	Unavailable	$298,920,811	4 / 7
2026-10-15	Unavailable	$298,920,811	4 / 7

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	1	6	2
2026-06-01	1	6	2
2026-07-01	1	6	2
2026-08-01	1	6	2
2026-09-01	1	6	2
2026-10-01	1	6	2

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 1 Buy / Strong Buy · 6 Hold · 2 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 16–Oct 15 · 0 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

Stifel NicolausOct 15

$10.00New observation · no comparable prior

$0$5.50$11.00

0 raises · 0 cuts · 0 unchanged · 1 without a comparable prior

How this is measured

Sep 16, 2026–Oct 15, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Retention of key management personnelPublished status: Under Pressure
Operating income improvement to $3.57MOperating income: $3.572M
Revenue stabilization around $290MPublished status: Under Pressure

Next proof point

Nov 5, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.6%Typical daily move · historical

Downside history

-67.0%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

SKINHEALTH SYSTEMS INC outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 10, 2026

What kind of bet this is

This investment represents a speculative growth opportunity. The company is currently loss-making, and while recent financial performance has been strong, management has faced challenges that create uncertainty.

What's priced into SKINHEALTH SYSTEMS INC

The market appears to price in a low level of fragility, suggesting that investors are not overly concerned about immediate risks. Valuation is seen as cheap compared to peers, but there is a significant expectations gap.

What the fundamentals likely do

Management has prioritized improving operating income and reducing net losses, showing some progress in recent quarters. However, revenue growth remains volatile, indicating challenges in stabilizing the top line.

What SKINHEALTH SYSTEMS INC hinges on

The future performance of SKIN will depend on broader sector trends and the success of key competitors. Additionally, the company's ability to manage executive transitions and deliver consistent financial results will be crucial.